Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) said on Wednesday that its product development partner has received final approval from the US Food and Drug Administration (FDA) for its AB-rated Abbreviated New Drug Application (ANDA) of generic Metrogel-Vaginal Gel (metronidazole vaginal gel 0.75%).
Under a pre-existing arrangement with its partner, the company will acquire full ownership of the generic ANDA within 30 days and anticipates launching metronidazole vaginal gel 0.75% immediately thereafter.
In the 12 months ending May 2019, the annual market sales for MetroGel-Vaginal were approximately USD100m as measured by IQVIA.
The generic Metrogel-Vaginal Gel is manufactured and was developed through the company's partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream